All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Ipsen Biopharmaceuticals, Lilly, and Pfizer. View funders.
Bookmark this article
Patients with relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma (CTCL) have poor outcomes.1 Overexpression of PD-L1 and CD30 is often observed in patients with PTCL (15–41% and 46–100%, respectively) and CTCL (27–73% and 47–76%, respectively).1 Nivolumab is a checkpoint inhibitor that targets PD-1/PD-L1 binding, and brentuximab vedotin (BV) is an anti-CD30 antibody-drug conjugate.1 BV was approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with CTCL, based on results from the phase III ALCANZA trial (NCT01578499) which were previously reported by the Lymphoma Hub.1
Zinzani et al.1 recently published an analysis of nivolumab plus BV in PTCL and CTCL cohorts of the phase I/II CheckMate 436 trial (NCT02581631) in Blood Advances, which we summarize below.
Response rates for the PTCL and CTCL cohorts are shown in Figure 1.
Figure 1. Response rates after nivolumab plus brentuximab vedotin treatment*
CTCL, cutaneous T-cell lymphoma; PTCL, peripheral T-cell lymphoma.
*Data from Zinzani, et al.1
Key learnings |
|
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox